China Profile Updated in ClinRegs
October 28, 2021
The China profile in ClinRegs has been reviewed and updated with the following information:
- New Personal Information Protection Law to ensure the safety of the personal information processed during clinical trials (See Definition of Sponsor and Quality, Data & Records Management)
- New regulation on the process and materials for requesting a pre-application meeting with the Center for Drug Evaluation (See Scope of Assessment, Submission Process, and Timeline of Review)
- Updated ethics committee guide (See the Ethics Committee, Clinical Trial Lifecycle, and Informed Consent topics)
- New pharmacological vigilance quality management standards for clinical trials (See Safety Reporting, Progress Reporting, Quality, Data & Records Management, Site/Investigator Selection, and IMP/IND Quality Requirements)
- New quality management guidelines for conduct during a clinical trial, including on adaptive design, multiplicity, pharmaceutical changes of innovative drugs, and new uses of drugs (See Quality, Data & Records Management and IMP/IND Quality Requirements)
- Updated postal information for the Ministry of Science and Technology which regulates human genetic resources (See Regulatory Authority)
Sources Added During this Update:
- (Guidance) Guidelines for the Construction of Ethical Review Committees for Clinical Research Involving People (EC-Guide – Standard Chinese) (October 2020)
Office of Medical Ethics Expert Committee of the National Health Commission and the Chinese Hospital Association - (Guidance) Guiding Principles for the Adaptive Design of Drug Clinical Trials (No. 6 of 2021) (NMPA-No6-2021 – Standard Chinese) (GoogleTranslate-NMPA-No6-2021) (January 29, 2021)
National Medical Products Administration, State Administration for Market Regulation - (Guidance) Guiding Principles for the Multiplicity of Drug Clinical Trials (No. 66 of 2020) (NMPA-No66-2021 – Standard Chinese) (GoogleTranslate-NMPA-No66-2021) (December 31, 2020)
National Medical Products Administration, State Administration for Market Regulation - (Guidance) Technical Guidelines for Clinical Trials of Improved New Chemical Drugs (No. 54 of 2020) (NMPA-No54-2020 – Standard Chinese) (GoogleTranslate-NMPA-No54-2020) (December 31, 2020)
National Medical Products Administration, State Administration for Market Regulation - (Guidance) Technical Guidelines for Pharmaceutical Changes During Clinical Trials of Innovative Drugs (No. 22 of 2021) (NMPA-No22-2021 – Standard Chinese) (GoogleTranslate-NMPA-No22-2021) (March 12, 2021)
National Medical Products Administration, State Administration for Market Regulation - (Legislation) Data Security Law of the People’s Republic of China (DataScrty) (Effective September 1, 2021)
National People’s Congress - (Legislation) Personal Information Protection Law of the People’s Republic of China (PIPL) (Effective November 1, 2021)
National People’s Congress - (Regulation) Information Security Technology Health and Medical Data Security Guidelines (DataScrty-Stds) (Effective July 1, 2021)
National Information Security Standardization Technical Committee - (Regulation) Management Measures for Communication and Exchange of Drug R&D and Technical Review (No. 48 of 2020) (NMPA-No48-2020) (GoogleTranslate-NMPA-No48-2018) (December 10, 2020)
National Medical Products Administration, State Administration for Market Regulation - (Regulation) Pharmacological Vigilance Quality Management Standards (No. 65 of 2021) (NMPA-No65-2021) (May 7, 2021)
National Medical Products Administration, State Administration for Market Regulation - (Regulation) Technical Requirements for Evaluation of Chemical Drugs Marketed Overseas But Not Marketed in China (No. 21 of 2021) (NMPA-No21-2021 – Standard Chinese) (GoogleTranslate-NMPA-No21-2021) (March 8, 2021)
National Medical Products Administration, State Administration for Market Regulation - (Article) China Passes Personal Information Protection Law (CHN-25) (September 10, 2021)
Ropes & Gray - (Article) In Review: The Life Sciences Regulatory Regime in China (CHN-20) (March 24, 2021)
Covington & Burling - (Article) Why Conduct Clinical Trials in China? A Regulatory Perspective (CHN-17) (April 2, 2021)
CR Medicon